Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,033 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Clotting Disorder Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT

NCT01006733
View directory record Official record
Conditions
Thromboembolism
Interventions
Pharmacogenetic, Target INR 1.8
Genetic · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
1,598 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
6
States / cities
Chicago, Illinois • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 20, 2026, 5:30 AM EDT
Recruiting No phase listed Observational

VCRC Tissue Repository

NCT02967068
View directory record Official record
Conditions
Aortitis, Cutaneous Vasculitis, Eosinophilic Granulomatosis With Polyangiitis, Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Henoch-Schonlein Purpura, IgA Vasculitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Churg-Strauss Syndrome
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
6
States / cities
Boston, Massachusetts • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A

NCT02172950
View directory record Official record
Conditions
Hemophilia A, Severe Hemophilia A
Interventions
rVIII-SingleChain
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
Male only
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
9
States / cities
San Diego, California • Aurora, Colorado • Hartford, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)

NCT03370913
View directory record Official record
Conditions
Hemophilia A
Interventions
valoctocogene roxaparvovec
Biological
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years and older · Male only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
15
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 20, 2026, 5:30 AM EDT
Recruiting No phase listed Observational

Vasculitis Pregnancy Registry

NCT02593565
View directory record Official record
Conditions
Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (GPA), Wegener's Granulomatosis, IgA Vasculitis, Henoch-Schoenlein Purpura (HSP), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Takayasu Arteritis (TAK), Urticarial Vasculitis, Systemic Vasculitis
Interventions
Online questionnaires
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 20, 2026, 5:30 AM EDT
Completed No phase listed Observational

ADVATE Post Authorization Safety Surveillance

NCT00214734
View directory record Official record
Conditions
Hemophilia A
Interventions
rAHF-PFM
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
37
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 20, 2026, 5:30 AM EDT
Withdrawn Not applicable Interventional

Operator and Patient Acceptance of Radiofrequency Cautery of the Biopsy Track During Percutaneous Liver, Kidney or Spleen Biopsy Procedures.

NCT05790109
View directory record Official record
Conditions
Bleeding Disorder, Spleen Lesion, Liver Diseases, Kidney Diseases
Interventions
RF track cautery during percutaneous organ biopsy
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

NCT03205163
View directory record Official record
Conditions
Hemophilia A
Interventions
Advate (Low Dose), Advate (High Dose), BIVV001 (Low Dose), BIVV001 (High Dose)
Biological
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 20, 2026, 5:30 AM EDT
Recruiting Phase 2 Interventional

Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)

NCT07136857
View directory record Official record
Conditions
Glanzmann Thrombasthenia
Interventions
EPTACOG BETA
Drug
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Lactoferrin Treatment in HIV Patients

NCT01830595
View directory record Official record
Conditions
HIV Infection
Interventions
Recombinant Lactoferrin, Placebo
Drug
Lead sponsor
Jason Baker
Other
Eligibility
40 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer

NCT00003451
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
recombinant interferon alfa, recombinant interleukin-12
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 20, 2026, 5:30 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Thromboelastography During Surgery for Malignant Pleural Mesothelioma

NCT01912547
View directory record Official record
Conditions
Coagulopathy, Mesothelioma
Interventions
Blood draw for TEG analysis
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2015 · Synced Oct 20, 2026, 5:30 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hemophilia A Research Program

NCT07414511
View directory record Official record
Conditions
Hemophilia A, Hemophilia A, Severe, Factor VIII (FVIII), FVIII Deficiency, Carrier of Hemophilia A, Inhibitors, Pregnancy, Maternal Blood Loss, Pregnancy Complications, Bleeding Disorder, Hemorrhage, Postpartum, Alloimmunization, X-Linked
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

NCT01167166
View directory record Official record
Conditions
Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Myeloproliferative Disease, Chronic Myeloid Leukemia
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 4 Interventional Results available

Octaplas Pediatric Plasma Replacement Trial

NCT02050841
View directory record Official record
Conditions
Liver Surgery, Liver Dysfunction, Coagulopathy, Cardiac Surgery
Interventions
octaplas
Biological
Lead sponsor
Octapharma
Industry
Eligibility
Up to 16 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Atlanta, Georgia • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Oct 20, 2026, 5:30 AM EDT
Completed No phase listed Observational

A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics

NCT02345356
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Cardiac Valvular Insufficiency, Coagulopathies, Pulmonary Embolism
Interventions
Genotype-guided, Standard-of-Care
Genetic · Other
Lead sponsor
University of Puerto Rico
Other
Eligibility
21 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Oct 20, 2026, 5:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thromboelastography to Assess Age-Related Coagulation Differences in Patients Undergoing Cesarean Delivery

NCT01416454
View directory record Official record
Conditions
Thrombophilia
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

NCT01423851
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
Interventions
NS-018
Drug
Lead sponsor
NS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
9
States / cities
Scottsdale, Arizona • San Diego, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Not applicable Interventional

Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases

NCT00376922
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Psychosocial Effects of Cancer and Its Treatment
Interventions
music therapy
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 20, 2026, 5:30 AM EDT
Completed No phase listed Observational

Trends in Transfusion Strategies and Outcomes in Trauma

NCT07603999
View directory record Official record
Conditions
Transfusion, Trauma Coagulopathy, Mortality, Blood Transfusion
Interventions
Not listed
Lead sponsor
Mariah Arif
Government
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 20, 2026, 5:30 AM EDT
Terminated Not applicable Interventional

nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Persistent & LSP AF

NCT00950092
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Numeris-AF Tethered Coagulation System with VisiTrax
Device
Lead sponsor
nContact Surgical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Venice, Florida • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Oct 20, 2026, 5:30 AM EDT
Terminated No phase listed Observational

Thrombin Generation and Thromboelastography in Non-overt DIC

NCT00299949
View directory record Official record
Conditions
Sepsis, Disseminated Intravascular Coagulation
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 20, 2026, 5:30 AM EDT
Terminated No phase listed Observational

Goal Attainment and Physical Activity in People With Hemophilia A

NCT06530030
View directory record Official record
Conditions
Hemophilia A
Interventions
efanesoctocog alfa
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 50 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency

NCT01253811
View directory record Official record
Conditions
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Interventions
catridecacog
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 6 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 20, 2026, 5:30 AM EDT